Suggested Remit: To appraise the clinical and cost effectiveness of nivolumab within its marketing authorisation for untreated advanced hepatocellular carcinoma.
Following on from information provided to NICE by the company in February 2021, the appraisal of Nivolumab for untreated advanced hepatocellular carcinoma [ID1248] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1248
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 23 November 2022 | Discontinued. Following on from information provided to NICE by the company in February 2021, the appraisal of Nivolumab for untreated advanced hepatocellular carcinoma [ID1248] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 05 February 2021 | Note added to the project documents |
| 16 April 2020 | Note added to the project documents |
| 16 April 2020 | Suspended. Topic is suspended |
| 08 April 2019 | Note added to the project documents |
| 12 October 2018 | Note added to the project documents |
| 09 May 2018 - 07 June 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 11 August 2017 | In progress. In progress |
For further information on our processes and methods, please see our CHTE processes and methods manual